NCT06280482View on ClinicalTrials.gov

Nicotinamide Riboside (NR) to Treat Moyamoya-like Cerebrovascular Disease in Smooth Muscle Dysfunction Syndrome (SMDS)

PHASE1RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 6, 2024

Primary Completion Date

July 25, 2027

Study Completion Date

July 25, 2027

Conditions
Smooth Muscle Dysfunction Syndrome (SMDS)
Interventions
DRUG

Nicotinamide riboside (NR)

Participants will take their weight-based dose of NR once daily by mouth with food for 60 days.

Trial Locations (1)

77030

RECRUITING

The University of Texas Health Science Center at Houston, Houston

All Listed Sponsors
lead

The University of Texas Health Science Center, Houston

OTHER